Physician profile
Daniel Borja Cacho
NPI 1710211503
$14,742.54
in general payments reported to CMS, 2019-2025
8 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2021: $906 · 2022: $3,851 · 2023: $9,101 · 2024: $250 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $9,000 · Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $9,000.00 |
| Food and Beverage | $832.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,030.24 | 2019-2023 | Davinci Xi, Da Vinci Surgical System |
| Fujifilm Healthcare Americas Corporation | $906.00 | 2021 | |
| Xvivo Perfusion INC. | $419.04 | 2024-2025 | Xvivo Perfusion System (Xps) |
| Sanofi-Aventis U.S. LLC | $109.45 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $107.60 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $95.03 | 2025 | |
| Conmed Corporation | $75.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Borja Cacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.